Kanghong Pharmaceutical subsidiary receives clinical trial approval

Chengdu Kanghong Pharmaceutical Group Co., Ltd. (SZSE:002773) announced that its subsidiary, Chengdu Kanghong Pharmaceutical Co., Ltd., has received a "Drug Clinical Trial Approval Notice" from the National Medical Products Administration for its Songling Xuemai Kang Capsules. The clinical trial will focus on assessing the drug's efficacy in treating functional ventricular premature beats. The capsules, classified as a traditional Chinese medicine (TCM) 2.3, are Kanghong's exclusive product. The company noted that uncertainties remain regarding the drug's development, clinical trial outcomes, and approval timelines, and advised investors to exercise caution. The drug's current approved functions include calming the liver and subduing yang, which will boost the core competitiveness of the product. The announcement was made on June 11, 2025.